SAN DIEGO, CA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases with unmet medical needs, has announced the publication of a scientific article in the peer-reviewed journal, Biomedicine & Pharmacotherapy, highlighting a new study providing additional data supporting the potential of EHP’s patented, first-in-class drug candidate, EHP-101, to treat fibrotic diseases, including cardiac fibrosis and systemic sclerosis (SSc). EHP is currently enrolling patients dosed with oral EHP-101 in a Phase IIa clinical trial for SSc (NCT04166552).
Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has been granted Fast Track designation from the US Food and Drug Administration (FDA) for its lead clinical-stage product candidate, EHP-101, for the treatment of systemic sclerosis (SSc), a severe form of scleroderma.